Benzene and Acute Myeloid Leukemia: Examining the Causal Link

From General Health to Occupational Risk

For decades, public health communication has centered on general wellness and the prevention of common diseases, often through lifestyle modifications and awareness of environmental factors. This legacy framework has successfully educated populations about broad health risks, from nutrition to infectious disease control. Within this context, discussions of chemical exposures have typically focused on acute poisoning or obvious irritants, leaving subtler, long-term occupational hazards less emphasized. As industrial processes expanded, however, the need to address specific workplace exposures became increasingly apparent. The transition from general health guidance to targeted occupational risk assessment requires a shift in focus: from population-wide advice to the particular vulnerabilities of workers in manufacturing environments. This pivot is especially relevant when considering substances like benzene, a solvent widely used in mass production settings. While the general public may encounter benzene through gasoline or cigarette smoke, occupational exposure presents a distinct concern due to higher concentrations and prolonged contact. Understanding the relationship between such exposure and the development of acute myeloid leukemia thus moves beyond general health science into the specialized domain of industrial hygiene and occupational medicine. This transition acknowledges that the same chemical, when encountered in the workplace, demands a more rigorous evaluation of risk and prevention strategies.

Benzene as a Recognized Carcinogen

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms, and it is able to augment the risk for the onset of acute myeloid leukemia (AML), myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Additionally, a meta-analysis of 25 studies found an increased risk of AML in children associated with benzene exposure, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Mechanisms and Clinical Context

Acute myeloid leukemia is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursor cells in the bone marrow and peripheral blood. Clinical presentation typically includes symptoms related to bone marrow failure, such as anemia, infection, and bleeding, as well as organ infiltration. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts, along with cytogenetic and molecular testing to classify subtypes and guide treatment. Benzene exposure is a known risk factor for AML, and the disease can develop after a latency period that varies depending on exposure intensity and duration. The mechanisms by which benzene induces AML are multifactorial. Possible mechanisms include a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Adequacy of Warnings and Exposure Assessment

Regarding the adequacy of warnings, benzene is acknowledged as a myelotoxin, and its carcinogenic ability has been reported (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure limits have been established in many jurisdictions, and material safety data sheets for benzene-containing products typically include warnings about cancer risk. However, the adequacy of these warnings may be questioned in light of evidence that even low-level exposure, such as ambient air pollution, can increase AML risk in children (https://pubmed.ncbi.nlm.nih.gov/41485753/). For affected patients, causation considerations involve documenting the history of benzene exposure, including occupational, environmental, or consumer product sources, and correlating this with the clinical timeline of AML development. The timeline between benzene exposure and documented harm can vary. In occupational settings, exposure at levels of 10 ppm or more has been associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). The latency period from initial exposure to AML diagnosis may span years to decades, depending on cumulative dose and individual susceptibility. In a national cohort from Switzerland, occupational exposure to benzene was associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). This underscores the importance of long-term follow-up for exposed populations. In summary, the evidence supports a causal link between benzene exposure and AML, with multiple mechanistic pathways involving genotoxicity, oxidative stress, and immunosuppression. Warnings about benzene's carcinogenicity exist but may need to be strengthened for lower-level exposures. Affected patients should be evaluated for exposure history, and the latency period between exposure and disease onset can be prolonged.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does benzene cause acute myeloid leukemia?

Yes, benzene is a recognized human carcinogen and a well-established cause of acute myeloid leukemia (AML). Multiple studies have confirmed a causal relationship between occupational benzene exposure and AML, with increased risk observed at exposure levels of 10 ppm or more (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What is the latency period between benzene exposure and AML?

The latency period from initial benzene exposure to AML diagnosis can span years to decades, depending on cumulative dose and individual susceptibility. Occupational studies indicate that prolonged exposure at levels of 10 ppm or more is associated with increased AML risk, and long-term follow-up of exposed populations is important (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.